NCT05027451View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of IXT-m200

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 25, 2021

Primary Completion Date

March 18, 2022

Study Completion Date

March 18, 2022

Conditions
Healthy
Interventions
DRUG

IXT-m200

Anti-methamphetamine chimeric monoclonal antibody (mAb)

OTHER

Placebo

Normal saline

Trial Locations (1)

07724

Clinilabs Drug Development Corporation, Eatontown

Sponsors
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

InterveXion Therapeutics, LLC

INDUSTRY